Tag: Immunotherapy
Adding Pembrolizumab Ups Survival in Stage III Undifferentiated Sarcoma
Benefit seen for stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdles
ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer
One-year progression-free survival, overall survival was 79.4, 89.6 percent; significantly longer survival seen in patients who achieved resectability
Tusamitamab Ravtansine Does Not Extend Survival With Nonsquamous NSCLC
Findings seen in patients previously treated with platinum-based chemotherapy and immunotherapy whose tumors highly expressed CEACAM5
Perioperative Nivolumab Beneficial for Resectable NSCLC
Perioperative nivolumab showed event-free survival benefit from time of surgery compared with neoadjuvant nivolumab
Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
Disparities seen based on income, education, and insurance status for both advanced kidney, bladder cancer
Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver Cancer
Rates of margin-negative resection and recurrence-free survival similar for neoadjuvant immunotherapy, surgery patients
Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver Cancer
Age and immune checkpoint inhibitor washout time inversely linked to allograft rejection; survival no different with, without allograft rejection
Gene Expression Signature Predicts Immune-Related Adverse Events in Melanoma Patients
Gene expression signature predicts irAEs in melanoma patients treated with ipilimumab/nivolumab
Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
Reduction seen in hypogammaglobulinemia, infections or severe infections, and associated antimicrobial use
Alternative Pembrolizumab Administration Yields Environmental Advantages
Weight-based, extended interval dosing and pharmacy-level stewardship strategies would result in fewer administration events
